Neuraxis Business Summary

Neuraxis, Inc. (NRXS) is a medical technology company that generates revenue through the sale of proprietary neuromodulation devices to hospitals and clinics, primarily targeting functional gastrointestinal disorders. Its business model is centered on its FDA-cleared Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, with primary segments including pediatric neuromodulation (IB-Stim) and diagnostic testing (Rectal Expulsion Device, or RED). As of early 2026, the company has transitioned into a high-growth phase following the activation of a permanent AMA Category I CPT code, which established a standardized reimbursement pathway for its therapies. In the competitive landscape, Neuraxis operates alongside medical equipment firms such as Sanara MedTech (SMTI), CVRx (CVRX), and Lucid Diagnostics (LUCD), positioning itself as a specialized leader in non-invasive, drug-free pediatric therapies for irritable bowel syndrome (IBS) while aggressively expanding into the adult and Veterans Affairs markets. The company was founded by Dr. Christopher Robin Brown, who continues to serve as a Director and the Director of Innovation. The leadership team is headed by President and CEO Brian Carrico, a med-tech veteran who has led the company since 2018, and CFO Timothy Henrichs, who brings over 20 years of global financial leadership from firms like General Electric and Renovo Home Partners. Other key executives include Dr. Adrian Miranda, Senior VP of Science & Technology and Chief Medical Officer, and Dr. Thomas Carrico, Chief Regulatory Officer. Neuraxis is backed by notable institutional investors including Rosalind Advisors, AIGH Capital Management, and Money Concepts Capital Corp, with a board of directors chaired by Bradley Watkins and featuring independent directors such as Gil Aharon and Beth Keyser.